Price Target Changed • Jul 14
Price target increased by 7.1% to CHF708 Up from CHF661, the current price target is an average from 7 analysts. New target price is 7.1% below last closing price of CHF763. Stock is up 21% over the past year. The company is forecast to post earnings per share of CHF21.45 for next year compared to CHF19.95 last year. Duyuru • Jul 13
EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026 EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026, at 10:30 W. Europe Standard Time. Reported Earnings • Feb 08
Full year 2025 earnings released: EPS: CHF19.97 (vs CHF19.70 in FY 2024) Full year 2025 results: EPS: CHF19.97 (up from CHF19.70 in FY 2024). Revenue: CHF1.95b (down 6.7% from FY 2024). Net income: CHF467.0m (up 1.3% from FY 2024). Profit margin: 24% (up from 22% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 4% per year and the company’s share price has also fallen by 4% per year. Duyuru • Jan 06
EMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Results on Feb 06, 2026 EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 results on Feb 06, 2026 Reported Earnings • Sep 01
First half 2025 earnings released: EPS: CHF10.71 (vs CHF10.66 in 1H 2024) First half 2025 results: EPS: CHF10.71 (up from CHF10.66 in 1H 2024). Revenue: CHF1.02b (down 6.2% from 1H 2024). Net income: CHF250.4m (flat on 1H 2024). Profit margin: 25% (up from 23% in 1H 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 3% per year. Upcoming Dividend • Aug 05
Upcoming dividend of CHF17.25 per share Eligible shareholders must have bought the stock before 12 August 2025. Payment date: 14 August 2025. Payout ratio is a comfortable 71% and the cash payout ratio is 90%. Trailing yield: 2.7%. Lower than top quartile of Swiss dividend payers (3.9%). In line with average of industry peers (2.8%). Duyuru • Jul 15
EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025 EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025, at 10:30 W. Europe Standard Time. Declared Dividend • Jul 14
Dividend increased to CHF17.25 Dividend of CHF17.25 is 7.8% higher than last year. Ex-date: 12th August 2025 Payment date: 14th August 2025 Dividend yield will be 2.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (71% earnings payout ratio) but not adequately covered by cash flows (90.1% cash payout ratio). The dividend has increased by an average of 3.7% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 13% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Jul 13
EMS-CHEMIE HOLDING AG announces Annual dividend, payable on August 14, 2025 EMS-CHEMIE HOLDING AG announced Annual dividend of CHF 13.9500 per share payable on August 14, 2025, ex-date on August 12, 2025 and record date on August 13, 2025. Duyuru • Apr 01
EMS-CHEMIE HOLDING AG to Report Fiscal Year 2024 Final Results on Jul 11, 2025 EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2024 final results on Jul 11, 2025 Reported Earnings • Mar 31
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: CHF19.70 (up from CHF19.56 in FY 2023). Revenue: CHF2.09b (down 5.5% from FY 2023). Net income: CHF460.8m (flat on FY 2023). Profit margin: 22% (up from 21% in FY 2023). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.6%. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 12% per year. Buy Or Sell Opportunity • Mar 10
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 7.2% to CHF677. The fair value is estimated to be CHF561, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 4.9% over the last 3 years. Earnings per share has declined by 7.8%. For the next 3 years, revenue is forecast to grow by 3.7% per annum. Earnings are also forecast to grow by 5.0% per annum over the same time period. Duyuru • Nov 27
EMS-CHEMIE HOLDING AG to Report Fiscal Year 2024 Results on Feb 07, 2025 EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2024 results on Feb 07, 2025 Duyuru • Oct 23
EMS-CHEMIE HOLDING AG to Report First Half, 2025 Results on Jul 11, 2025 EMS-CHEMIE HOLDING AG announced that they will report first half, 2025 results on Jul 11, 2025 Board Change • Sep 17
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 02
First half 2024 earnings: EPS and revenues miss analyst expectations First half 2024 results: EPS: CHF10.66 (up from CHF10.49 in 1H 2023). Revenue: CHF1.09b (down 8.1% from 1H 2023). Net income: CHF249.4m (up 1.6% from 1H 2023). Profit margin: 23% (up from 21% in 1H 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates by 4.8%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 10% per year. Upcoming Dividend • Aug 06
Upcoming dividend of CHF19.25 per share Eligible shareholders must have bought the stock before 13 August 2024. Payment date: 15 August 2024. Payout ratio is a comfortable 65% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Swiss dividend payers (4.4%). Higher than average of industry peers (1.7%). Price Target Changed • Jul 16
Price target increased by 8.2% to CHF731 Up from CHF675, the current price target is an average from 8 analysts. New target price is approximately in line with last closing price of CHF708. Stock is up 2.6% over the past year. The company is forecast to post earnings per share of CHF20.29 for next year compared to CHF19.56 last year. Declared Dividend • Jul 15
Dividend of CHF19.25 announced Shareholders will receive a dividend of CHF19.25. Ex-date: 13th August 2024 Payment date: 15th August 2024 Dividend yield will be 2.6%, which is lower than the industry average of 2.8%. Sustainability & Growth Dividend is covered by both earnings (65% earnings payout ratio) and cash flows (71% cash payout ratio). The dividend has increased by an average of 3.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 24% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Apr 03
EMS-CHEMIE HOLDING AG to Report Fiscal Year 2023 Final Results on Jul 12, 2024 EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2023 final results on Jul 12, 2024 Reported Earnings • Mar 22
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: CHF19.71 (down from CHF22.75 in FY 2022). Revenue: CHF2.19b (down 12% from FY 2022). Net income: CHF461.0m (down 13% from FY 2022). Profit margin: 21% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.8%. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 11
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: CHF19.71 (down from CHF22.75 in FY 2022). Revenue: CHF2.19b (down 12% from FY 2022). Net income: CHF461.0m (down 13% from FY 2022). Profit margin: 21% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.8%. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Duyuru • Jan 09
EMS-CHEMIE HOLDING AG to Report Fiscal Year 2023 Results on Feb 09, 2024 EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2023 results on Feb 09, 2024 Duyuru • Oct 31
EMS-CHEMIE HOLDING AG to Report First Half, 2024 Results on Jul 12, 2024 EMS-CHEMIE HOLDING AG announced that they will report first half, 2024 results on Jul 12, 2024 Duyuru • Oct 11
EMS-CHEMIE HOLDING AG to Report Q3, 2023 Results on Oct 31, 2023 EMS-CHEMIE HOLDING AG announced that they will report Q3, 2023 results on Oct 31, 2023 Reported Earnings • Sep 01
First half 2023 earnings released: EPS: CHF10.48 (vs CHF12.19 in 1H 2022) First half 2023 results: EPS: CHF10.48 (down from CHF12.19 in 1H 2022). Revenue: CHF1.18b (down 7.9% from 1H 2022). Net income: CHF245.0m (down 14% from 1H 2022). Profit margin: 21% (down from 22% in 1H 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Duyuru • Aug 31
EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 10, 2024 EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 10, 2024. Upcoming Dividend • Aug 08
Upcoming dividend of CHF20.00 per share at 2.8% yield Eligible shareholders must have bought the stock before 15 August 2023. Payment date: 17 August 2023. Payout ratio is a comfortable 69% but the company is paying out more than the cash it is generating. Trailing yield: 2.8%. Lower than top quartile of Swiss dividend payers (4.1%). Lower than average of industry peers (4.0%). Reported Earnings • Mar 29
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: CHF22.87 (down from CHF23.53 in FY 2021). Revenue: CHF2.44b (up 7.0% from FY 2021). Net income: CHF535.0m (down 2.8% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 7% per year. Reported Earnings • Feb 13
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: CHF22.87 (down from CHF23.53 in FY 2021). Revenue: CHF2.44b (up 7.0% from FY 2021). Net income: CHF535.0m (down 2.8% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%. Revenue is forecast to stay flat during the next 2 years compared to a 6.2% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 2% per year. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Independent Non-Executive Director Christoph Mader was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Price Target Changed • Oct 31
Price target decreased to CHF757 Down from CHF849, the current price target is an average from 7 analysts. New target price is 20% above last closing price of CHF630. Stock is down 31% over the past year. The company is forecast to post earnings per share of CHF23.96 for next year compared to CHF23.53 last year. Buying Opportunity • Oct 27
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be CHF830, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 3.1%. Revenue is forecast to grow by 6.8% in 2 years. Earnings is forecast to grow by 7.6% in the next 2 years. Price Target Changed • Oct 26
Price target decreased to CHF826 Down from CHF902, the current price target is an average from 7 analysts. New target price is 24% above last closing price of CHF665. Stock is down 29% over the past year. The company is forecast to post earnings per share of CHF24.02 for next year compared to CHF23.53 last year. Duyuru • Oct 18
EMS-CHEMIE HOLDING AG to Report Q3, 2022 Results on Oct 25, 2022 EMS-CHEMIE HOLDING AG announced that they will report Q3, 2022 results on Oct 25, 2022 Reported Earnings • Sep 01
First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First half 2022 results: EPS: CHF12.20 (up from CHF11.89 in 1H 2021). Revenue: CHF1.28b (up 10% from 1H 2021). Net income: CHF285.0m (up 2.5% from 1H 2021). Profit margin: 22% (down from 24% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.9%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 6.2%, compared to a 13% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 6% per year. Upcoming Dividend • Aug 09
Upcoming dividend of CHF21.00 per share Eligible shareholders must have bought the stock before 16 August 2022. Payment date: 18 August 2022. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of Swiss dividend payers (4.0%). Higher than average of industry peers (1.8%). Duyuru • Jul 16
EMS-CHEMIE HOLDING AG Proposes Dividend EMS-CHEMIE HOLDING AG proposed a dividend payment of total CHF 21.00 (CHF 17.00) per share at the to be held ordinary annual general meeting held on August 13, 2022. Buying Opportunity • Jun 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 10.0%. The fair value is estimated to be CHF947, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.4% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.0% per annum. Earnings is also forecast to grow by 8.7% per annum over the same time period. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Christoph Maeder was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Apr 20
EMS-CHEMIE HOLDING AG to Report Q1, 2022 Results on Apr 27, 2022 EMS-CHEMIE HOLDING AG announced that they will report Q1, 2022 results on Apr 27, 2022 Reported Earnings • Mar 28
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: CHF23.53 (up from CHF18.57 in FY 2020). Revenue: CHF2.28b (up 25% from FY 2020). Net income: CHF550.3m (up 27% from FY 2020). Profit margin: 24% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 11%, compared to a 11% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Reported Earnings • Feb 13
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: CHF23.64 (up from CHF18.57 in FY 2020). Revenue: CHF2.25b (up 23% from FY 2020). Net income: CHF553.0m (up 27% from FY 2020). Profit margin: 25% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 10%, compared to a 9.4% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Buying Opportunity • Jan 24
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 3.1%. The fair value is estimated to be CHF1,149, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 7.2% per annum over the last 3 years. Earnings per share has declined by 4.1% per annum over the last 3 years. Board Change • Dec 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Christoph Maeder was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 01
First half 2021 earnings released: EPS CHF11.89 (vs CHF8.17 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CHF1.17b (up 38% from 1H 2020). Net income: CHF278.0m (up 46% from 1H 2020). Profit margin: 24% (up from 23% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Upcoming Dividend • Aug 03
Upcoming dividend of CHF17.00 per share Eligible shareholders must have bought the stock before 10 August 2021. Payment date: 12 August 2021. Trailing yield: 1.7%. Lower than top quartile of Swiss dividend payers (3.5%). Higher than average of industry peers (1.2%). Price Target Changed • Jul 26
Price target increased to CHF936 Up from CHF844, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CHF966. Stock is up 21% over the past year. Price Target Changed • Apr 24
Price target increased to CHF801 Up from CHF712, the current price target is an average from 5 analysts. New target price is 9.3% below last closing price of CHF883. Stock is up 39% over the past year. Reported Earnings • Mar 27
Full year 2020 earnings released: EPS CHF18.57 (vs CHF22.54 in FY 2019) The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CHF1.83b (down 17% from FY 2019). Net income: CHF434.3m (down 18% from FY 2019). Profit margin: 24% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 26
New 90-day low: CHF805 The company is down 2.0% from its price of CHF819 on 27 November 2020. The Swiss market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF585 per share.